These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 32707816

  • 21. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.
    Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL.
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [Abstract] [Full Text] [Related]

  • 22. Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.
    Ma SR, Deng WW, Liu JF, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ.
    Mol Cancer; 2017 Jun 07; 16(1):99. PubMed ID: 28592285
    [Abstract] [Full Text] [Related]

  • 23. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.
    J Immunother Cancer; 2019 Jul 15; 7(1):184. PubMed ID: 31307547
    [Abstract] [Full Text] [Related]

  • 24. Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy.
    Miraki Feriz A, Bahraini F, Khosrojerdi A, Azarkar S, Sajjadi SM, HosseiniGol E, Honardoost MA, Saghafi S, Silvestris N, Leone P, Safarpour H, Racanelli V.
    PLoS One; 2023 Jul 15; 18(12):e0295863. PubMed ID: 38096229
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
    Tsujikawa T, Ohno K, Morita KI, Saburi S, Mitsuda J, Yoshimura K, Kimura A, Morimoto H, Ogi H, Shibata S, Akashi T, Kurata M, Imoto I, Shimizu Y, Kano S, Watanabe A, Yamazaki T, Asada Y, Hayashi R, Saito Y, Ozawa H, Tsukahara K, Oridate N, Sano D, Horii A, Ueki Y, Maruo T, Mukoyama N, Hanai N, Fukusumi T, Iwai H, Fujisawa T, Fujii T, Nibu KI, Iwae S, Ueda T, Chikuie N, Yasumatsu R, Matsuo M, Umeno H, Ono T, Masuda M, Toh S, Itoh K, Hirano S, Asakage T.
    Front Immunol; 2024 Jul 15; 15():1390873. PubMed ID: 39136017
    [Abstract] [Full Text] [Related]

  • 27. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M, Raza A, Inchakalody VP, Nashwan AJJ, Allahverdi N, Krishnankutty R, Uddin S, Zar Gul AR, Al Homsi MU, Dermime S.
    Front Immunol; 2018 Jul 15; 9():1769. PubMed ID: 30108590
    [Abstract] [Full Text] [Related]

  • 28. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
    Brix N, Dunn L, Seiwert T, Belka C, Lauber K.
    Internist (Berl); 2020 Jul 15; 61(7):682-689. PubMed ID: 32462252
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE, McCusker MG, Mehra R.
    Expert Opin Emerg Drugs; 2020 Dec 15; 25(4):501-514. PubMed ID: 33196319
    [Abstract] [Full Text] [Related]

  • 31. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B, Young RJ, Rischin D.
    Semin Cancer Biol; 2018 Oct 15; 52(Pt 2):228-240. PubMed ID: 29355614
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients.
    Kirchner J, Plesca I, Rothe R, Resag A, Löck S, Benešová I, Rupp L, Linge A, Wehner R, Krause M, Schmitz M.
    Front Immunol; 2024 Oct 15; 15():1414298. PubMed ID: 38938577
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H, Zhao Q, Zhang Y, Zhang Q, Zheng Z, Liu S, Liu Z, Meng L, Xin Y, Jiang X.
    Front Immunol; 2021 Oct 15; 12():652054. PubMed ID: 34305889
    [Abstract] [Full Text] [Related]

  • 36. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L, Mao L, Liu JF, Chen L, Yu GT, Yang LL, Wu H, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ.
    Cancer Immunol Res; 2019 Oct 15; 7(10):1700-1713. PubMed ID: 31387897
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients.
    Botticelli A, Cirillo A, d'Amati G, Di Gioia C, Corsi A, Della Rocca C, Santini D, Carletti R, Pisano A, Polimeni A, De Vincentiis M, Valentini V, di Cristofano C, Romeo U, Cerbelli E, Messineo D, De Felice F, Leopizzi M, Cerbelli B.
    Pathol Res Pract; 2024 Aug 15; 260():155415. PubMed ID: 38996615
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.